RO 23-6457 prolongs survival of vascularized allografts in rodents and primates.
The ability of RO 23-6457, a retinoid compound with marked in vitro immunosuppressive properties, to prolong vascularized allografts was examined in several in vivo transplantation models. In the murine heterotopic heart model, efficacy was shown in two H-2 incompatible strain combinations, with indefinite graft survival at some doses. In the rat heterotopic heart model, oral administration prolonged Wistar-Furth grafts in Lewis hosts an average of 1 week, with no long-term survivors at a variety of doses. Given subcutaneously, grafts were further prolonged, but the compound proved toxic. In a bilaterally nephrectomized renal transplant model in cynomolgus monkeys treated intravenously at a dose of 2 mg/kg/day, host survival was prolonged to 18, 32, 33, and 74 days, compared with 11, 11, 12, 13, and 26 days in untreated controls (P less than 0.05 by rank-sum testing). The three shorter surviving recipients died from anorexia and weight loss with normal renal function, while the longest survivor rejected its kidney when exhaustion of iv sites precluded further treatment. The toxic effects of the compound resemble the syndrome of hypervitaminosis A. RO 23-6457 will prolong graft survival as a single agent, justifying further preclinical testing and efforts to reduce toxicity.
Kirkman
R L
RL
Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts.
Barrett
L V
LV
Carter
P
P
Reed
M H
MH
Shapiro
M E
ME
D000818:Animals; D006085:Graft Survival / Q000187:drug effects*; D016027:Heart Transplantation; D016030:Kidney Transplantation; D008252:Macaca fascicularis; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D051381:Rats; D011920:Rats, Inbred WF; D016042:Transplantation, Heterotopic; D014184:Transplantation, Homologous; D014212:Tretinoin / Q000031:analogs & derivatives* / Q000494:pharmacology
C061340:Ro 23-6457; D014212:Tretinoin